Wall Street analyst estimates for Metagenomi, Inc. Common Stock (MGX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases.
Valuation Ratios
| Price / Book | 0.38 |
| EV / EBITDA | -0.48 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $243000 | $17.2M | $44.8M | $52.3M | $25.2M |
| Cost of Revenue | $387000 | $1.7M | $94.4M | 0 | $5.3M |
| Gross Profit | -$144000 | $15.5M | -$49.6M | $52.3M | $19.9M |
| Research & Development | $14.5M | $43.1M | $94.4M | $109.2M | $94.4M |
| Selling, General & Admin | $9.7M | $18.7M | $28.8M | $32.0M | $26.8M |
| Operating Expenses | $23.8M | $60.1M | $28.8M | $141.2M | $115.9M |
| Operating Income | -$23.9M | -$44.6M | -$78.5M | -$88.9M | -$96.0M |
| EBITDA | -$20.8M | -$39.2M | -$56.0M | -$78.2M | -$82.6M |
| Interest Expense | $302000 | $98000 | 0 | 0 | 0 |
| Pre-tax Income | -$21.4M | -$41.0M | -$60.2M | -$83.6M | -$87.9M |
| Income Tax | 0 | $2.6M | $8.0M | -$5.5M | -$58000 |
| Net Income | -$21.4M | -$43.6M | -$68.3M | -$78.1M | -$87.9M |
| EPS | $-3.62 | $-1.16 | $-1.82 | $-2.09 | $-2.36 |
| EPS (Diluted) | $-3.62 | $-1.16 | $-1.82 | $-2.09 | $-2.36 |
| Shares Outstanding (Diluted) | $5.9M | $37.5M | $37.5M | $37.4M | $37.3M |
Price
| Price | $1.15 |
| Market Cap | $43M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADVM · ALXO · ARTV · ATYR · CNTB · DTIL · IFRX
Explore sector: Healthcare · Biotechnology
More sections of MGX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks